No guidelines exist in the approach that Evidence Review Groups (ERGs) should take to appraise search methodologies in the manufacturer's submission (MS) in single technology appraisals (STA). As a result, ERGs are left to appraise searches using their own approach. This study investigates the limitations of manufacturers' search methodologies as critiqued by ERGs in published STA reports. METHODS: Limitations from search critiques in 83 ERG reports published in the NIHR website between 2006 and May 2011 were extracted. The limitations were grouped into themes. Comparisons were made between limitations reported in the clinical effectiveness versus cost-effectiveness searches. RESULTS: Over 60 different limitations were identified and sorted in seven broad themes: missing studies, search strategy, reporting, sources, limits, filters and translation. The search strategy theme contained the most limitations. Missing studies were frequently found by the ERG group in the clinical effectiveness searches. The omission of searches by manufacturers for unpublished and ongoing trials was frequently reported by the ERG. By contrast, failure of the manufacturer to report strategies was the most common limitation in the cost-effectiveness searches which may explain the number of missing critiques in some ERG reports. Themes with the most frequent limitations in both types of searches are search strategy, reporting and source. CONCLUSIONS: Variations exist in the limitations reported in both clinical and cost-effectiveness evidence searches in STAs. It is recommended that separate checklists or one that incorporates both reporting and search strategy appraisal be used to ensure that ERG groups and manufacturers are aware of the range of limitations that might exist when appraising searches. 
PHP164 PAYER INFORMATION REQUIREMENTS FOR RELATIVE EFFECTIVENESS ASSESSMENT VARY ACROSS MARKETS AND CREATE DISCREPENCIES IN PATIENT ACCESS TO MEDICINES

IHS Global Insight, London, UK
OBJECTIVES: To 1) evaluate how relative effectiveness assessment (REA) is used within the national pricing and reimbursement (P&R) processes in 8 developed and emerging markets; 2) to understand payer REA requirements and preferences in each of the markets studied; and 3) to analyse how the process impacts patient access to medicines across geographies. METHODS: IHS studied national P&R processes through primary and secondary research to establish how REA is leveraged to rationalise reimbursement and control price levels. Over 30 key relative effectiveness assessors and P&R decision makers were interviewed to understand the level and type of relative effectiveness evidence they look for in practice, broken down by public versus private sector, primary versus secondary-care segment, and key therapeutic areas. This research was further supported by real-life REA case studies across key therapeutic areas. RESULTS: The evaluation of the therapeutic value of a medicine can result in P&R decision discrepancies across markets. These coverage disparities notably reflect societal and methodological differences in the way the available evidence is interpreted across markets. In terms of how therapeutic value is factored into P&R decisions, markets can be segmented into two broad categories: 1) those that rely on economic evaluation to assess therapeutic value, and 2) those that evaluate the added therapeutic value/improvement in actual clinical benefit without considering associated costs. In terms of information needs, payers wish to be in a position to evaluate how new medicines compare with the standard of care in their specific health care setting and in their patient population when making their P&R decisions. CONCLUSIONS: REA will increasingly be used in future to rationalise finite health care resources and budgets. For now there are two schools when it comes to the methodology and patient access to medicines is more stringent in countries that undertake economic evaluation.
PHP165 EXPLORING THE ROLE OF THE COMMITTEE IN THE NICE APPRAISAL PROCESS: HOW CONSISTENT ARE DECISIONS ACROSS COMMITTEES?
McCann E, Plested M HERON, Luton, UK OBJECTIVES: NICE technology appraisals are reviewed by one of four committees (A to D). Given the standard submission template, the information submitted as part of the appraisal process is the same across submissions. Therefore, committees may be expected to make similar decisions regarding the acceptance or rejection of submissions. This research explored whether there were differences in acceptances or rejections between committees and which factors affected those decisions. METHODS: Final appraisal determinations (FADs) from October 2009 to May 2012 were identified and reviewed. The committee, decision, and reasons for the decision were extracted from the FADs. Rates of acceptance or rejection were compared across the four committees using Fisher's exact test. The composition of each committee and the considered therapy area were also assessed. RESULTS: This research considered 53 submissions, from which 63 recommendations were generated. Committee A made the highest proportion of positive recommendations (75%) and Committee D made the lowest proportion (50%). The background of committee members was similar between Committees A and B, and between C and D, but differed between those two sets. However, the number of acceptances or rejections did not differ significantly by committee (pϭ0.560). Limitations in clinical evidence were cited as a reason for rejection more frequently than limitations in economic evidence across all committees. The considered therapy areas differed between committees though cancer was the most commonly-appraised area; Committee C reviewed the highest proportion of cancer submissions. For this therapy area, the rate of acceptance or rejection did not differ significantly by committee (pϭ0.126). CONCLUSIONS: The likelihood of positive or negative recommendations did not appear to vary by the committee assessing the submission. Given the reasons for negative recommendations and the proportion of academic committee members, maximising the quality and rigour of submitted evidence is a rational approach to the appraisal process. To assess the impact of these models on recommendations, all relevant reports were reviewed with respect to the health economic conclusion, modeling methods and further research needs. RESULTS: A total of 90 DAHTA-reports incorporate an economic assessment. Of these, ten reports develop a new specific decision-analytic model. About 30% of the reports without a model come to a general economic conclusion but only one report gives a clear recommendation without major limitations. About 20% of these reports explicitly state that the development of a model for the German setting may have helped to come to a clear conclusion. In contrast, all reports incorporating a model give an economic recommendation -two of these with limitations. The identified models differ with respect to the type of health economic evaluation (cost-effectiveness, cost-utility), model type (decision tree, Markov model, Monte Carlo simulation), time horizon (two weeks -life long), discount rate (3%, 5%), perspective (statutory health insurance, care provider, social), outcome parameters (generic, disease specific) and sensitivity analyses (one-way, multi-way, probabilistic).
PHP167
CONCLUSIONS:
Incorporating decision-analytic models in German HTAs has the potential to increase the number of health economic recommendations, but only a fraction of reports developed a specific model so far. 
PHP168 CALCULATED FORECAST FOR TECHNICAL OBSOLESCENCE IN COMPUTERISED TOMOGRAPHY EQUIPMENT
OBJECTIVES: To estimate the useful life of Computerised Tomography Equipment (CT) METHODS:
A main components analysis in this methodology has allowed for a reduction in the number of variables on the survey-file in Computerised Tomography technology and facilitates subsequent work without a significant loss of information. The Log Binomial Regression Model has enabled probability calculations on answers (technology leap) to the different levels of stimuli (changes in variables, temporary development, detection system, imaging resolution and equipment power). Using a Discriminant analysis, the objective has been to estimate, based on time, the chances of a technological leap occurring. RESULTS: The 18 evaluated technical parameters in Computerised Tomography Technology have been grouped in three main components: Detection System which explains 72.4% of the variance; Imaging Resolution which explaining 13.55% of the variance and Equipment Power explaining 7.1% of the variance. Logistic regression allows us to approximate the influence of each main component with the passing of time, the implementation of a technology leap, with its significant influence with positive signs of temporary evolution (0.430), and with a negative sign for the main component the detection system(Ϫ3.974), image resolution (Ϫ3.766) and equipment power (Ϫ2.460). For Determinant analysis, the explanatory variables used in the model are the 3 components calculated. The prediction model obtains a lower percentage of success than the Log Binomial, around 66.7%. The most important factor in influencing the change of technology seems to be the image resolution followed by the detection system and a negative sing for temporary evolution. CONCLUSIONS: The results of the present project will enable advance knowledge of the expectations of technological change in CT technology, allowing an advance in investment planning for this technology, for acquiring and installing this type of technology. Hungarian guideline represented nearly the same methodological aspects for example in the choice of comparator, time horizon, discount rate and financial impact analysis. We appraised relevant differences in the perspective of the PE studies, preferred analytical technic (CMA, CEA, CUA, CBA), systematic review of evidences, costs to be included, preferred outcome measure and deliver utility. The QALY is the preferred health outcome measure in cost utility studies almost in every European countries, however only the English and Scottish guidelines require only EQ-5D profile to deliver utility. In the new version of the Hungarian guideline the discount rate will be changed from 5% to 3,7%, the cost-effectiveness threshold will be explicitly determined (twofold and threefold of GDP per capita) and the direct comparisons will be preferred instead of indirect comparisons. CONCLUSIONS: Generally we concluded that the Hungarian guideline published in 2002 and also the new modified version basicly require the same approach and expectations as the European ones. Change in three main things (discount rate, cost-effectivess threshold, direct comparison preference) makes our guidelines more elaborated that could help the rational decision-making. The explicitly determined cost-effectiveness threshold requires specification in the method of delivering utility in the future. METHODS: Therefore, santésuisse (the national association of sick funds) and Interpharma (representing the interests of the Swiss research-based pharmaceutical industry) initiated "SwissHTA", a transparent and inclusive project designed to develop a national consensus how Switzerland might better use HTAs. The process was led by a project team, with membership from santésuisse (and Helsana), Interpharma (and Roche), the Swiss federal government (BAG), the Swiss Medical Association (FMH), and the Swiss Academy of Medical Sciences (SAMW). After seven retreats of the project team and three workshops in the course of 12 months, the team reached a consensus. RESULTS: The Swiss HTA consensus statement emphasizes the need for a broad technology focus (covering both new and existing ones by specific approaches following a common set of core principles) and recommends opportunities for stakeholder involvement throughout the HTA processes. Primary evaluation criteria should be determined by the social preferences of the Swiss population, constrained by a prior normative commitment in line with constitutional provisions and the principled, rights-based legal tradition of Switzerland. The full range of health-related benefits should be evaluated, and assessment of clinical evidence should take into account the level of evidence that can reasonably be expected in a given context, rating the degree of confidence in outcomes in relation to the relevance and the magnitude of the effects observed. Economic viability should be evaluated based on budgetary impact and cost benefit ratios, whereas the consensus rejects the idea of uniform cost per QALY benchmarks. CONCLUSIONS: The Swiss HTA consensus combines a pragmatic approach with well-defined evolutionary options. 
PHP169 COMPARING THE HUNGARIAN METHODOLOGICAL GUIDELINE FOR CONDUCTING ECONOMIC EVALUATION OF HEALTH CARE INTERVENTION WITH EUROPEAN GUIDELINES
PHP170 THE SWISS HEALTH TECHNOLOGY ASSESSMENT (HTA) CONSENSUS: GUIDING PRINCIPLES
PHP171 HTA PRINCIPLES INCLUSION IN NEW EUROPEAN UNION MEMBER STATES
OBJECTIVES:
HTA has the increasing role in decision-making process in new EU member states. Health care systems miscellaneousness causes differences in HTA exploitation and its characteristics. Our objective was to make an overview of HTA within these countries to show similarities and its differences. METHODS: Literature search was done on governmental and governmental like sites to find HTA related Acts, regulation, guidelines or other relevant documents which describes HTA country specific approach in new EU member states. First search was relevant to presence of HTA. In those of them where HTA is defined in legislation we compared several characteristics: model, role, type of HTA, role of pharmacoeconomic, threshold, discounting factor, sensitivity analysis and differentiation of approaches between therapeutic and prophylactic approaches. RESULTS: Out of 12 new EU member states (accessed in May 2004 or later) 10 applies HTA, 8 as light version, 2 as robust NICE like version. HTA has impactful position in 5 of them (Poland, Slovenia, Slovakia, Estonia and Latvia). Only Poland applies full HTA approach. Rest of countries use narrow pharmacoeconomic approach. Threshold is officially published in primary legislation in 2 countries (Poland, Slovakia). Discounting factor varies between 3% and 5%. There was no difference recognized in evaluation of either therapeutic or prophylactic approaches. CONCLUSIONS: HTA form and role differ in new EU member states, but some similarities were identified. These similarities cannot presume any transferability of HTA decision, as it depends on the other factors like health care system, composition of costs and methods of its reimbursement by different bodies within relevant country. But certain common areas for cooperation could be established based on that. 
HEALTH CARE USE & POLICY STUDIES -Patient Registries & Post-Marketing Studies
PHP172 CHALLENGES IN DEVELOPING A NEW SYSTEM FOR REGISTRATION OF PATIENT REGISTRIES
OBJECTIVES:
Patient registries are an important tool for many types of clinical research, including studies of comparative effectiveness, cost effectiveness, treatment patterns, patient outcomes, and natural history of disease. Use of registries is increasing, but there is no central database in the U.S. designed specifically to list patient registries. A searchable public database that is designed to provide information about patient registries would support research collaborations, reduce redundancies, encourage the efficient use of resources, and improve transparency in observational clinical research. The goal of this project, funded by the Agency for Healthcare Research and Quality, is to design and develop a Registry of Patient Registries (RoPR) system that meets the needs of a diverse set of stakeholders. METHODS: Stakeholders from a broad range of organizations and with varying levels of familiarity with patient registries were identified and invited to participate in a series of remote and in-person meetings to gather and refine the RoPR system requirements. Requirements were also revised through public comment and usability and pilot testing. Over 320 individuals participated in RoPR design activities. RESULTS: Stakeholders identified a range of challenges facing the RoPR system. Challenges include improving understanding of the distinction between observational studies, patient registries, and other types of clinical research; determining how to provide useful information to assess registry quality; ensuring that registry listings are sufficiently complete; and motivating registry sponsors to list their registries in a voluntary system. CONCLUSIONS: In response to stakeholder feedback, the RoPR was designed as an integrated system with ClinicalTrials.gov that collects information on registry purpose, classification, objectives, data collected, progress reports, and interest in collaboration and data sharing. Some challenges identified through stakeholder discussions were addressed in the system design. Other challenges must be addressed through education and collection of stakeholder feedback following the RoPR launch in September 2012. OBJECTIVES: Disability is a global public health priority strongly related to socioeconomic status (SES). Social capital (SC) is a complex construct and little is known about how it relates to SES and disability in a middle-income country. This study's purpose was to explore this relationship in Chile. METHODS: Cross-sectional analysis of Chilean National Health Survey-2010 (nϭ5037). Health outcome: Composite index of disability (continuous variable, range 0-100). Dependent variables: a) SES measures: household income per capita (tertiles), educational level (primary/secondary/higher), employment status (yes/no), and household assets index (tertiles). b) SC dimensions: interpersonal trust (3 variables), financial/emotional support (2 variables) and social participation (2 variables). After factor analysis, s 2 factors explained 60% variance (low uniqueness in all variables), with exception of social participation which was assess separately. After orthogonal-varimax-rotation, 2 continuous aggregated variables were considered for analysis: trust and social support. Kaiser-Meyer-Olkinϭ0.62; Cronbach alphaϭ0.64 and 0.78 for trust and social support, respectively. c) Demographic factors: age, sex, marital status, rural/urban Weighted multiple linear regression models analyzed in R. Confounding and multiple interactions terms were explored. RESULTS: Mean of disability was 18.8pts. A significant crude association between disability and SES was observed. All dimensions of SC were significantly associated with disability (Trust: Ϫ7.6pts, Support: Ϫ10.7pts, Participation:Ϫ2.0pts). Adjusted regressions showed SES reduced the magnitude of its association to disability by 70% when dimensions of SC were added to the model, but remained significant. Social participation lost statistical significance in presence of SES. Multiplicative interaction terms were found between SC and education, providing additional higher chance to be disabled when being poorly educated and having low trust and support. CONCLUSIONS: There is a complex relationship between disability, SES and SC. Interactions between SES and SC significantly modify the chance of being disabled and this needs further consideration in the context of a middle-income country.
HEALTH CARE USE & POLICY STUDIES -Population Health
PHP173 DISENTANGLING THE RELATIONSHIP BETWEEN DISABILITY, SOCIOECONOMIC STATUS AND SOCIAL CAPITAL IN CHILE: A POPULATION-BASED STUDY
PHP174 PHYSICAL ACTIVITY MATTERS: THE ASSOCIATIONS BETWEEN BODY MASS INDEX, PHYSICAL ACTIVITY AND HEALTH-REALTED QUALITY-OF-LIFE TRAJECTORIES OVER 10 YEARS
